A 35-year-old woman with a BRCA2 mutation developed IDC that was ER-, progesterone receptor (PgR)-negative, and HER2-negative, as a primary breast cancer during surveillance, 2 years after receiving her genetic testing results. This evidence concerns the gene PGR and breast cancer.